|
1
|
Johnston FM and Beckman M: Updates on
management of gastric cancer. Curr Oncol Rep. 21(67)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA A Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rawla P and Barsouk A: Epidemiology of
gastric cancer: Global trends, risk factors and prevention. Prz
Gastroenterol. 14:26–38. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wagner AD, Syn NL, Moehler M, Grothe W,
Yong WP, Tai BC, Ho J and Unverzagt S: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev.
8(CD004064)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Park SR, Chun JH, Kim YW, Lee JH, Choi IJ,
Kim CG, Lee JS, Bae JM and Kim HK: Phase II study of low-dose
Docetaxel/Fluorouracil/Cisplatin in metastatic gastric carcinoma.
Am J Clin Oncol. 28:433–438. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sun DS, Jeon EK, Won HS, Park JC, Shim BY,
Park SY, Hong YS, Kim HK and Ko YH: Outcomes in elderly patients
treated with a single-agent or combination regimen as first-line
chemotherapy for recurrent or metastatic gastric cancer. Gastric
Cancer. 18:644–652. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Narahara H, Iishi H, Imamura H, Tsuburaya
A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C and Sakata Y:
Randomized phase III study comparing the efficacy and safety of
irinotecan plus S-1 with S-1 alone as first-line treatment for
advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer.
14:72–80. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van De Velde CJH, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Laurén P: The two histological main types
of gastric carcinoma: Diffuse and So-called Intestinal-type
carcinoma: An attempt at a Histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Carneiro F, Seixas M and Sobrinho-Simões
M: New elements for an updated classification of the carcinomas of
the stomach. Pathol Res Pract. 191:571–584. 1995.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu
K, Zeng Q, Zeng L, Pan Y, Chen ZS, et al: Signaling pathways and
therapeutic interventions in gastric cancer. Signal Transduct
Target Ther. 7(358)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Monster JL, Kemp LJS, Gloerich M and Van
Der Post RS: Diffuse gastric cancer: Emerging mechanisms of tumor
initiation and progression. Biochim Biophys Acta Rev Cancer.
1877(188719)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Organisation mondiale de la santé and
Centre international de Recherche Sur le cancer: Digestive system
tumours. 5th edition. International agency for research on cancer,
Lyon, 2019.
|
|
14
|
Ajani JA, D'Amico TA, Bentrem DJ, Chao J,
Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al:
Gastric cancer, version 2.2022, NCCN clinical practice guidelines
in oncology. J Natl Compr Canc Netws. 20:167–192. 2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Davidson B and Tropé CG: Ovarian cancer:
Diagnostic, biological and prognostic aspects. Womens Health
(Lond). 10:519–533. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Roepman P, Schlicker A, Tabernero J,
Majewski I, Tian S, Moreno V, Snel MH, Chresta CM, Rosenberg R,
Nitsche U, et al: Colorectal cancer intrinsic subtypes predict
chemotherapy benefit, deficient mismatch repair and
epithelial-to-mesenchymal transition. Int J Cancer. 134:552–562.
2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J
and Shi B: Breast cancer intrinsic subtype classification, clinical
use and future trends. Am J Cancer Res. 5:2929–2943.
2015.PubMed/NCBI
|
|
18
|
Talhouk A and McAlpine JN: New
classification of endometrial cancers: The development and
potential applications of genomic-based classification in research
and clinical care. Gynecol Oncol Res Pract. 3(14)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
West L, Vidwans SJ, Campbell NP, Shrager
J, Simon GR, Bueno R, Dennis PA, Otterson GA and Salgia R: A novel
classification of lung cancer into molecular subtypes. PLoS One.
7(e31906)2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
The Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu
S, Cristescu R, Nebozhyn M, Gong L, Yue YG, et al: Genomic
landscape and genetic heterogeneity in gastric adenocarcinoma
revealed by whole-genome sequencing. Nat Commun.
5(5477)2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chia NY and Tan P: Molecular
classification of gastric cancer. Ann Oncol. 27:763–769.
2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Alsina M, Arrazubi V, Diez M and Tabernero
J: Current developments in gastric cancer: From molecular profiling
to treatment strategy. Nat Rev Gastroenterol Hepatol. 20:155–170.
2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Setia N, Agoston AT, Han HS, Mullen JT,
Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A,
Lennerz JK, et al: A protein and mRNA expression-based
classification of gastric cancer. Modern Pathol. 29:772–784.
2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Organisation mondiale de la santé and
Centre international de Recherche Sur le cancer: Female genital
tumours. 5th edition. International agency for research on cancer,
Lyon, 2020.
|
|
27
|
Ramos MFKP, Pereira MA, Amorim LC, Mello
ES, Faraj SF, Ribeiro U, Hoff PMG, Cecconello I and Castria TB:
Gastric cancer molecular classification and adjuvant therapy: Is
there a different benefit according to the subtype? J Surg Oncol.
121:804–813. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ahn S, Lee SJ, Kim Y, Kim A, Shin N, Choi
KU, Lee CH, Huh GY, Kim KM, Setia N, et al: High-throughput Protein
and mRNA Expression-based classification of gastric cancers can
identify clinically distinct subtypes, concordant with recent
molecular classifications. Am J Surg Pathol. 41:106–115.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhao C, Feng Z, He H, Zang D, Du H, Huang
H, Du Y, He J, Zhou Y and Nie Y: Protein expression-based
classification of gastric cancer by immunohistochemistry of tissue
microarray. PLoS One. 15(e0238836)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Park S, Ahn S, Kim DG, Kim H, Kang SY and
Kim KM: High frequency of juxtamembrane domain ERBB2 mutation in
gastric cancer. Cancer Genomics Proteomics. 19:105–112.
2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Robichaux JP, Elamin YY, Vijayan RSK,
Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, et
al: Pan-cancer landscape and analysis of ERBB2 mutations identifies
poziotinib as a clinically active inhibitor and enhancer of T-DM1
activity. Cancer Cell. 36:444–457.e7. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Karczewski KJ, Francioli LC, Tiao G,
Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A,
MacArthur DG, et al: The mutational constraint spectrum quantified
from variation in 141,456 humans. Nature. 581:434–443.
2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discovery. 2:401–404.
2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: A new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697.
2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wilding B, Scharn D, Böse D, Baum A,
Santoro V, Chetta P, Schnitzer R, Botesteanu DA, Reiser C, Kornigg
S, et al: Discovery of potent and selective HER2 inhibitors with
efficacy against HER2 exon 20 insertion-driven tumors, which
preserve wild-type EGFR signaling. Nat Cancer. 3:821–836.
2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhu Y, Zhu X, Wei X, Tang C and Zhang W:
HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev
Cancer. 1876(188549)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kahraman S and Yalcin S: Recent advances
in systemic treatments for HER-2 positive advanced gastric cancer.
Onco Targets Ther. 14:4149–4162. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Adua D, Di Fabio F, Rojas Llimpe FL, Pini
S and Pinto C: Long-term survival in an advanced gastric cancer
patient treated with cetuximab in association with FOLFIRI: A case
report. J Gastrointest Oncol. 5:E13–E17. 2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Satoh T, Lee KH, Rha SY, Sasaki Y, Park
SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, et al:
Randomized phase II trial of nimotuzumab plus irinotecan versus
irinotecan alone as second-line therapy for patients with advanced
gastric cancer. Gastric Cancer. 18:824–832. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Muro K, Chung HC, Shankaran V, Geva R,
Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al:
Pembrolizumab for patients with PD-L1-positive advanced gastric
cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial.
Lancet Oncol. 17:717–726. 2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Janjigian YY, Bendell J, Calvo E, Kim JW,
Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, et al:
CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab
plus ipilimumab in patients with metastatic esophagogastric cancer.
J Clin Oncol. 36:2836–2844. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kim JW, Lee HS, Nam KH, Ahn S, Kim JW, Ahn
SH, Park DJ, Kim HH and Lee KW: PIK3CA mutations are associated
with increased tumor aggressiveness and Akt activation in gastric
cancer. Oncotarget. 8:90948–90958. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Te Paske IBAW, Garcia-Pelaez J, Sommer AK,
Matalonga L, Starzynska T and Jakubowska A: Solve-RD-GENTURIS
group. van der Post RS, Lubinski J, Oliveira C, et al: A mosaic
PIK3CA variant in a young adult with diffuse gastric cancer: Case
report. Eur J Hum Genet. 29:1354–1358. 2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Polom K, Das K, Marrelli D, Roviello G,
Pascale V, Voglino C, Rho H, Tan P and Roviello F: KRAS mutation in
gastric cancer and prognostication associated with microsatellite
instability status. Pathol Oncol Res. 25:333–340. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Salem M, El-Refai S, Sha W, Grothey A,
Puccini A, George T, Hwang J, Kadakia K, Musselwhite L, Van Cutsem
E, et al: O-3 Characterization of KRAS mutation variants and
prevalence of KRAS-G12C in gastrointestinal malignancies. Ann
Oncol. 32(S218)2021.
|
|
48
|
Osterlund E, Ristimäki A, Kytölä S, Kuopio
T, Heervä E, Muhonen T, Halonen P, Kallio R, Soveri LM, Sundström
J, et al: KRAS-G12C mutation in one Real-life and three
population-based Nordic cohorts of metastatic colorectal cancer.
Front Oncol. 12(826073)2022.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Chida K, Kotani D, Masuishi T, Kawakami T,
Kawamoto Y, Kato K, Fushiki K, Sawada K, Kumanishi R, Shirasu H, et
al: The prognostic impact of KRAS G12C mutation in patients with
metastatic colorectal cancer: A multicenter retrospective
observational study. Oncologist. 26:845–853. 2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ambrosini M, Del Re M, Manca P, Hendifar
A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark
K, et al: ALK inhibitors in patients with ALK Fusion-positive GI
cancers: An international data set and a molecular case series. JCO
Precis Oncol. 6(e2200015)2022.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Chon HJ, Kim HR, Shin E, Kim C, Heo SJ,
Lee C, Park JK, Noh SH, Chung HC and Rha SY: The Clinicopathologic
features and prognostic impact of ALK positivity in patients with
resected gastric cancer. Ann Surg Oncol. 22:3938–3945.
2015.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Smolen GA, Sordella R, Muir B, Mohapatra
G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi
DC, et al: Amplification of MET may identify a subset of cancers
with extreme sensitivity to the selective tyrosine kinase inhibitor
PHA-665752. Proc Natl Acad Sci USA. 103:2316–2321. 2006.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Bachleitner-Hofmann T, Sun MY, Chen CT,
Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB,
et al: HER kinase activation confers resistance to MET tyrosine
kinase inhibition in MET oncogene-addicted gastric cancer cells.
Mol Cancer Ther. 7:3499–3508. 2008.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki
H, Ito H and Tahara E: Frequent amplification of the c-met gene in
scirrhous type stomach cancer. Biochem Biophys Res Commun.
189:227–232. 1992.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Seruca R, Suijkerbuijk RF, Gärtner F,
Criado B, Veiga I, Olde-Weghuis D, David L, Castedo S and
Sobrinho-Simões M: Increasing levels of MYC and MET
co-amplification during tumor progression of a case of gastric
cancer. Cancer Genet Cytogenet. 82:140–145. 1995.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Tsujimoto H, Sugihara H, Hagiwara A and
Hattori T: Amplification of growth factor receptor genes and DNA
ploidy pattern in the progression of gastric cancer. Virchows
Archiv. 431:383–389. 1997.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Sakakura C, Mori T, Sakabe T, Ariyama Y,
Shinomiya T, Date K, Hagiwara A, Yamaguchi T, Takahashi T, Nakamura
Y, et al: Gains, losses, and amplifications of genomic materials in
primary gastric cancers analyzed by comparative genomic
hybridization. Genes Chromosom Cancer. 24:299–305. 1999.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Janjigian YY, Tang LH, Coit DG, Kelsen DP,
Francone TD, Weiser MR, Jhanwar SC and Shah MA: MET expression and
amplification in patients with localized gastric cancer. Cancer
Epidemiol Biomarkers Prev. 20:1021–1027. 2011.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Xu B, Chen F, Zhang X, Wang Z, Che K, Wu
N, Yu L, Fan X, Liu B and Wei J: Antigen-Specific T cell
immunotherapy targeting Claudin18.2 in gastric cancer. Cancers.
14(2758)2022.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Grizzi G, Venetis K, Denaro N, Bonomi M,
Celotti A, Pagkali A, Hahne JC, Tomasello G, Petrelli F, Fusco N,
et al: Anti-Claudin treatments in gastroesophageal adenocarcinoma:
Mainstream and upcoming strategies. J Clin Med.
12(2973)2023.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Qi C, Gong J, Li J, Liu D, Qin Y, Ge S,
Zhang M, Peng Z, Zhou J, Cao Y, et al: Claudin18.2-specific CAR T
cells in gastrointestinal cancers: Phase 1 trial interim results.
Nat Med. 28:1189–1198. 2022.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Sahin U, Türeci Ö, Manikhas G, Lordick F,
Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B,
et al: FAST: A randomised phase II study of zolbetuximab (IMAB362)
plus EOX versus EOX alone for first-line treatment of advanced
CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Ann Oncol. 32:609–619. 2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Alexa M, Hasenburg A and Battista MJ: The
TCGA molecular classification of endometrial cancer and its
possible impact on adjuvant treatment decisions. Cancers.
13(1478)2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Wedden S, Miller K, Frayling IM, Thomas T,
Chefani A, Miller K, Hamblin A, Taylor JC and D'Arrigo C:
Colorectal cancer stratification in the routine clinical pathway: A
district general hospital experience. Appl Immunohistochem Mol
Morphol. 27:e54–e62. 2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Fremond S, Andani S, Barkey Wolf J,
Dijkstra J, Melsbach S, Jobsen JJ, Brinkhuis M, Roothaan S,
Jurgenliemk-Schulz I, Lutgens LCHW, et al: Interpretable deep
learning model to predict the molecular classification of
endometrial cancer from haematoxylin and Eosin-stained Whole-slide
images: A combined analysis of the PORTEC randomised trials and
clinical cohorts. Lancet Digital Health. 5:e71–e82. 2023.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Fell C, Mohammadi M, Morrison D,
Arandjelović O, Syed S, Konanahalli P, Bell S, Bryson G, Harrison
DJ and Harris-Birtill D: Detection of malignancy in whole slide
images of endometrial cancer biopsies using artificial
intelligence. PLoS One. 18(e0282577)2023.PubMed/NCBI View Article : Google Scholar
|
